Behzad B. Bidadi

Hematology | Oncology

19 Bradhurst Ave Ste 1400
Hawthorne, NY 10532

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 16 publications

Clinical and economic burden of recurrence among older patients with locoregionally advanced head and neck squamous cell carcinoma in the United States.

Clinical and economic burden of recurrence among older patients with locoregionally advanced head and neck squamous cell carcinoma in the United States.

Journal: Journal of managed care & specialty pharmacy

Published: May 21, 2026

Lenvatinib plus pembrolizumab versus standard of care in recurrent/metastatic head and neck squamous cell carcinoma: Randomized, phase 2 LEAP-009 trial.

Lenvatinib plus pembrolizumab versus standard of care in recurrent/metastatic head and neck squamous cell carcinoma: Randomized, phase 2 LEAP-009 trial.

Journal: European journal of cancer (Oxford, England : 1990)

Published: February 10, 2026

Correction: Real-world treatment patterns and clinical outcomes among elderly patients with locoregionally advanced head and neck squamous cell carcinoma in the United States.

Correction: Real-world treatment patterns and clinical outcomes among elderly patients with locoregionally advanced head and neck squamous cell carcinoma in the United States.

Journal: Frontiers in oncology

Published: February 05, 2026

Randomized Controlled Trials Comparing the Standard of Care to Alternative Treatments in Patients with Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma: A Systematic Literature Review.

Randomized Controlled Trials Comparing the Standard of Care to Alternative Treatments in Patients with Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma: A Systematic Literature Review.

Journal: Advances in therapy

Published: January 13, 2026

Health-related quality of life outcomes from KEYNOTE-412: chemoradiotherapy with or without pembrolizumab in participants with head and neck squamous cell carcinoma.

Health-related quality of life outcomes from KEYNOTE-412: chemoradiotherapy with or without pembrolizumab in participants with head and neck squamous cell carcinoma.

Journal: Frontiers in oncology

Published: June 11, 2025

Corrigendum to "PD-L1 testing patterns in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) in the U.S." [Oral Oncol. 161 (2025) 107146].

Corrigendum to "PD-L1 testing patterns in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) in the U.S." [Oral Oncol. 161 (2025) 107146].

Journal: Oral oncology

Published: April 12, 2025

Real-world treatment patterns and clinical outcomes among elderly patients with locoregionally advanced head and neck squamous cell carcinoma in the United States.

Real-world treatment patterns and clinical outcomes among elderly patients with locoregionally advanced head and neck squamous cell carcinoma in the United States.

Journal: Frontiers in oncology

Published: April 06, 2025

Lenvatinib Plus Ifosfamide and Etoposide in Children and Young Adults With Relapsed Osteosarcoma: A Phase 2 Randomized Clinical Trial.

Lenvatinib Plus Ifosfamide and Etoposide in Children and Young Adults With Relapsed Osteosarcoma: A Phase 2 Randomized Clinical Trial.

Journal: JAMA oncology

Published: October 17, 2024

PD-L1 testing patterns in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) in the U.S.

PD-L1 testing patterns in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) in the U.S.

Journal: Oral oncology

Published: August 22, 2024

Real-world use of first-line pembrolizumab + platinum + taxane combination regimens in recurrent / metastatic head and neck squamous cell carcinoma.

Real-world use of first-line pembrolizumab + platinum + taxane combination regimens in recurrent / metastatic head and neck squamous cell carcinoma.

Journal: Frontiers in oncology

Published: December 01, 2023

Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (KEYNOTE-412): a randomised, double-blind, phase 3 trial.

Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (KEYNOTE-412): a randomised, double-blind, phase 3 trial.

Journal: The Lancet. Oncology

Published: October 27, 2023

Pembrolizumab given concomitantly with chemoradiation and as maintenance therapy for locally advanced head and neck squamous cell carcinoma: KEYNOTE-412.

Pembrolizumab given concomitantly with chemoradiation and as maintenance therapy for locally advanced head and neck squamous cell carcinoma: KEYNOTE-412.

Journal: Future oncology (London, England)

Published: June 04, 2020

Showing 1-12 of 16

Last Updated: 09/26/2026